[NEJM] 2023年6月8日分


June 8, 2023 Vol. 388 No. 23

①Transplantation Outcomes with Donor Hearts after Circulatory Death
 [NEJM QUICK TAKE] 心停止ドナーからの心臓移植の転帰

②Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy
 [NEJM QUICK TAKE] 妊娠早期に妊娠糖尿病を治療する

③Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
 [NEJM QUICK TAKE] 子宮体癌に対するドスタルリマブ

④Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
 [NEJM QUICK TAKE] 進行子宮体癌に対するペムブロリズマブ


①,transplantation of hearts obtained from donors after circulatory death,心停止ドナー心の移植
①,hearts obtained from donors after brain death,脳死ドナー心
①,heart that had been preserved with the use of traditional cold storage after the brain death of the donor,ドナーの脳死後従来の冷保存法で保存されていた脳死ドナー心
①,as-treated circulatory-death group,実際に受けた治療に基づく(as-treated)心停止群
①,brain-death group,脳死群
①,mean per-patient number of serious adverse events associated with the heart graft at 30 days after transplantation,移植後 30 日の時点での移植心に関連する重篤な有害事象
①,donor heart that had been reanimated and assessed with the use of extracorporeal nonischemic perfusion after circulatory death,ドナーの心停止後に体外非虚血性灌流で蘇生させ,評価した心臓の移植
②,gestational diabetes,妊娠糖尿病
②,maternal and infant health,母子の健康
②,women between 4 weeks’ and 19 weeks 6 days’ gestation who had a risk factor for hyperglycemia and a diagnosis of gestational diabetes (World Health Organization 2013 criteria),高血糖の危険因子を有し,妊娠糖尿病(世界保健機関 [WHO] 診断基準 2013 に基づく)と診断された妊娠 4 週~19 週 6 日の女性
②,oral glucose-tolerance test,経口ブドウ糖負荷試験
②,”pregnancy-related hypertension (preeclampsia, eclampsia, or gestational hypertension)”,妊娠関連高血圧(妊娠高血圧腎症,子?,妊娠高血圧症)
②,neonatal lean body mass,新生児除脂肪体重
③,immune-checkpoint inhibitor that targets the programmed cell death 1 receptor,プログラム細胞死 1(PD-1)受容体を標的とする免疫チェックポイント阻害薬
③,endometrial cancer,子宮体癌
③,eligible patients with primary advanced stage III or IV or first recurrent endometrial cancer,原発性進行 III 期または IV 期子宮体癌,もしくは初回再発子宮体癌の適格患者
③,area under the concentration-time curve,血中濃度-時間曲線下面積
③,”progression-free survival as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1″,固形癌治療効果判定基準(RECIST)バージョン 1.1 に基づき試験担当医師が評価した無増悪生存
③,mismatch repair-deficient (dMMR),ミスマッチ修復機構欠損(dMMR)
③,microsatellite instability?high (MSI-H) tumors,高頻度マイクロサテライト不安定性(MSI-H)腫瘍
③,patients with primary advanced or recurrent endometrial cancer,原発性進行または再発子宮体癌患者
④,standard first-line chemotherapy for endometrial cancer,子宮体癌に対する標準的な一次化学療法
④,patients with measurable disease (stage III or IVA) or stage IVB or recurrent endometrial cancer,測定可能病変を有する(III 期または IVA 期)子宮体癌,IVB 期子宮体癌,再発子宮体癌のいずれかを有する患者